• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition

    3/8/23 5:00:00 PM ET
    $NLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NLTX alert in real time by email

    SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Neoleukin does not expect to disclose or provide an update concerning developments related to this process until the Company enters into definitive agreements or arrangements with respect to a transaction or otherwise determines that other disclosure is necessary or appropriate.

    In connection with the evaluation of strategic alternatives, the Board of Directors of Neoleukin also approved a further corporate restructuring to preserve cash, including a reduction in the Company's workforce by approximately 70%. Chief Executive Officer Jonathan Drachman, M.D., will also be stepping down after a short transition. The Company expects this reduction in force to be completed during the first half of 2023.

    "The work that Neoleukin has done to advance the science of de novo protein design for immunotherapeutic use, including what we believe is the first in-human clinical trial of a de novo protein, is important and impressive. However, based on the anticipated time and investment necessary to further develop the technology and potential product candidates in this challenging capital markets environment, we believe that it is appropriate to pursue other strategic options," said Todd Simpson, Chairman of the Board of Neoleukin. "It was a difficult decision to restructure our workforce as we conduct this review of strategic alternatives; however, we believe it was a prudent decision that will maximize shareholder value. We would like to thank Jonathan, the research team, and all employees who have worked on these ground-breaking advancements."

    About Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.  For more information, please visit the Neoleukin website: www.neoleukin.com.

    Contact:

    Media

    Julie Rathbun

    206-769-9219

    [email protected]



    Primary Logo

    Get the next $NLTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NLTX

    DatePrice TargetRatingAnalyst
    3/2/2022$30.00 → $25.00Overweight
    Piper Sandler
    8/6/2021$30.00Overweight
    Piper Sandler
    More analyst ratings

    $NLTX
    SEC Filings

    See more
    • SEC Form 144 filed by Neoleukin Therapeutics Inc.

      144 - Neurogene Inc. (0001404644) (Subject)

      2/9/24 4:35:58 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Neurogene Inc. (0001404644) (Filer)

      1/5/24 7:11:07 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Shareholder Director Nominations, Regulation FD Disclosure

      8-K - Neurogene Inc. (0001404644) (Filer)

      12/19/23 7:31:02 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Woods Robert Keith

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 7:01:01 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Palekar Rohan

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 6:58:27 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Noonberg Sarah B.

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 6:56:12 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Neoleukin Therapeutics with a new price target

      Piper Sandler reiterated coverage of Neoleukin Therapeutics with a rating of Overweight and set a new price target of $25.00 from $30.00 previously

      3/2/22 8:41:36 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Neoleukin Therapeutics with a new price target

      Piper Sandler resumed coverage of Neoleukin Therapeutics with a rating of Overweight and set a new price target of $30.00

      8/6/21 7:21:14 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

      SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbo

      12/14/23 7:00:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

      SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin's common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin's existing trading symbol "NLTX" with a new CUSIP number 64049K203. The reverse

      9/22/23 8:00:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of HCCI, PRDS, NLTX, CCF

      NEW YORK, July 22, 2023 (GLOBE NEWSWIRE) -- Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HCCI to an investment affiliate of J.F. Lehman & Company for $45.50 per share in cash for each share of HCCI common stock owned. If you are a HCCI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Pardes Biosciences, Inc. (NASDAQ:PRDS) Lifshitz Law PLLC announces an investigation into possible breach of fiducia

      7/22/23 8:07:00 PM ET
      $CCF
      $HCCI
      $NLTX
      $PRDS
      Building Products
      Consumer Discretionary
      Miscellaneous
      Industrials